Table 2.
Control | HCM | |
---|---|---|
n | 20 | 50 |
Echocardiography | ||
Left atrial volume (ml/BSA) | 27.6±8.9 | 45.3±15.5*** |
E/A ratio | 1.38±0.36 | 1.35±0.56 |
Deceleration time (ms) | 182.1±27.0 | 213.2±57.3* |
Septal e’ (cm/s) | 10.6±2.9 | 6.1±1.6*** |
Lateral e’ (cm/s) | 13.7±3.5 | 8.3±2.8*** |
Mean e’ (cm/s) | 12.1±3.0 | 7.2±2.0*** |
Septal E/e’ | 8.5±2.6 | 13.9±5.5*** |
Lateral E/e’ | 6.3±1.9 | 10.7±5.0*** |
Mean E/e’ | 7.8±2.6 | 12.2±4.8*** |
Resting LVOT gradient (mmHg) | 5.2±1.2 | 38.5±45.1** |
CMR | ||
Septal thickness (mm) | 8.3±1.8 | 19.2±4.8*** |
Lateral wall thickness (mm) | 7.9±1.5 | 8.6±1.8 |
Septal/lateral wall thickness | 1.1±0.1 | 2.3±0.6*** |
LV mass (g) | 113.1±20.6 | 171.1±61.6*** |
LV mass index (g/BSA) | 57.5±8.0 | 86.2±28.0*** |
LV ejection fraction (%) | 60.9±5.8 | 69.5±7.3** |
LVEDV (mL) | 180.4±29.1 | 160.3±38.6 |
LVEDV indexed (mL/BSA) | 91.9±11.5 | 78.0±21.8 |
LVESV (mL) | 72.4±22.6 | 48.3±20.4*** |
LVSV (mL) | 108.0±7.8 | 106.5±35.2 |
Presence of LGE (%) | NA | 86% |
Quantity of LGE (% of LV) mass | NA | 5.1±6.7 |
T1 times (ms), excluding LGE | 578.4±45.4 | 497.5±79.2* |
T1 times (ms), including LGE | 578.4±45.4 | 481.2±83.8** |
T1 times (ms, corrected values) | 566.3±49.6 | 478.6±80.9** |
Blood T1 times (ms) | 303.1±13.7 | 334.6±31.5 |
Data are expressed as mean ± SD. CMR: Cardiac magnetic resonance; LVOT: Left ventricular outflow tract; LV: Left ventricular; LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; LVSV: Left ventricular stroke volume; LGE: Late gadolinium enhancement; BSA: Body surface area; T1 times (corrected values): T1 times were normalized to a matched state (time post-contrast administration =20 minutes, eGFR =90 mL/min/1.73 m2) to account for the potential effects of glomerular filtration rate, time delay post-contrast administration, and contrast agent relaxivity on gadolinium pharmacokinetics.
P<0.05, vs. controls;
P<0.01, vs. controls;
P<0.001, vs. controls.